Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
DEPO DepoMed Inc. daily Stock Chart
DepoMed Inc.
Index- P/E24.36 EPS (ttm)0.78 Insider Own0.50% Shs Outstand60.31M Perf Week-4.14%
Market Cap1.15B Forward P/E13.35 EPS next Y1.42 Insider Trans-1.63% Shs Float59.61M Perf Month-29.58%
Income67.80M PEG0.81 EPS next Q0.20 Inst Own77.30% Short Float16.85% Perf Quarter-37.73%
Sales372.80M P/S3.07 EPS this Y173.30% Inst Trans0.11% Short Ratio5.65 Perf Half Y-24.18%
Book/sh5.77 P/B3.29 EPS next Y132.14% ROA7.80% Target Price28.50 Perf Year33.99%
Cash/sh1.96 P/C9.71 EPS next 5Y30.00% ROE20.30% 52W Range13.55 - 33.74 Perf YTD17.94%
Dividend- P/FCF29.61 EPS past 5Y46.60% ROI25.60% 52W High-43.69% Beta1.52
Dividend %- Quick Ratio1.60 Sales past 5Y46.60% Gross Margin91.20% 52W Low40.22% ATR1.61
Employees324 Current Ratio1.70 Sales Q/Q39.60% Oper. Margin39.60% RSI (14)34.27 Volatility7.00% 8.56%
OptionableYes Debt/Eq2.34 EPS Q/Q-271.40% Profit Margin18.20% Rel Volume0.46 Prev Close18.73
ShortableYes LT Debt/Eq2.34 EarningsNov 05 AMC Payout0.00% Avg Volume1.78M Price19.00
Recom2.40 SMA20-16.65% SMA50-29.13% SMA200-19.49% Volume816,029 Change1.44%
Jul-30-15Downgrade RBC Capital Mkts Outperform → Sector Perform $26 → $32
Jul-24-15Reiterated WallachBeth Hold $26 → $33
Jul-14-15Reiterated ROTH Capital Buy $28.50 → $33
Jun-11-15Initiated Morgan Stanley Equal-Weight $23
May-12-15Reiterated RBC Capital Mkts Outperform $29 → $26
Apr-22-15Initiated Piper Jaffray Overweight $37
Apr-06-15Reiterated ROTH Capital Buy $27 → $30
Mar-13-15Downgrade WallachBeth Buy → Hold $28 → $26
Jan-16-15Upgrade ROTH Capital Neutral → Buy $25
Jan-16-15Reiterated RBC Capital Mkts Outperform $20 → $22
Dec-10-14Initiated RBC Capital Mkts Outperform $20
Jul-10-14Initiated WallachBeth Buy $17
Feb-25-13Downgrade WallachBeth Buy → Hold $8 → $7
Jan-05-12Initiated JMP Securities Mkt Outperform $8
Sep-30-11Initiated Auriga Buy $10
Feb-18-10Downgrade Merriman Buy → Neutral
Oct-21-09Initiated Caris & Company Buy $9
Oct-12-09Reiterated Merriman Buy $11.50 → $7.50
Oct-05-09Initiated Merriman Buy
Jun-20-08Initiated Roth Capital Buy $5
Oct-09-15 08:09AM  Horizon passes regulatory hurdle in pursuit of Depomed
Oct-06-15 11:55AM  DEPO: NUCYNTA Has the Blockbuster Potential -7.84%
Oct-01-15 10:10AM  Facing hostile takeover, East Bay drug company execs buy more stock at
10:08AM  How Did IBBs Top 5 Pharmaceutical Small Caps Perform?
Sep-30-15 04:08PM  Squashed Takeovers And Positive Test Results Propelling These Stocks Higher at Insider Monkey +21.61%
Sep-28-15 04:47PM  10 Stocks Moving In Monday's After-Hours Session -22.14%
03:41PM  War of words heats up in $2 billion East Bay drug company takeover bid at
06:30AM  Depomed Issues Statement on ISS Report PR Newswire
Sep-23-15 10:12AM  Stock to Watch: J.C. Penney, Heron Therapeutics, Intra-Cellular Therapies at The Wall Street Journal
09:24AM  Depomed Says It Receives Favorable Patent Decision at The Wall Street Journal
08:00AM  Depomed Announces Two Favorable Decisions in Inter Partes Review Proceedings Versus Endo Pharmaceuticals PR Newswire
Sep-22-15 01:25PM  Why DepoMed is Falling 10% Today at Motley Fool -12.68%
Sep-17-15 08:02AM  DEPOMED INC Files SEC form 8-K, Other Events
Sep-16-15 06:04AM  DEPOMED INC Files SEC form 8-K, Other Events
Sep-15-15 05:18PM  DEPOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  Depomed Files New Patent Infringement Lawsuit Against NUCYNTA(R) ER ANDA Filer PR Newswire
Sep-14-15 04:26PM  Depomed rejects Horizon's latest takeover offer
11:36AM  DepoMed Urges Holders to Reject Horizon Offer at The Wall Street Journal
08:00AM  Depomed's Board of Directors Rejects Horizon Pharma plc's Unsolicited Exchange Offer PR Newswire
Sep-10-15 08:00AM  Depomed to Present at the Morgan Stanley Global Healthcare Conference PR Newswire
Sep-09-15 10:00AM  Depomed and The American Migraine Foundation Join Forces to Highlight Need for the Proper Diagnosis, Management and Treatment of Migraine PR Newswire
Sep-08-15 04:10PM  Pay no attention to that $2 billion offer, East Bay company tells shareholders at
10:11AM  Horizon takes hostile Depomed bid directly to shareholders
09:17AM  Depomed Issues Statement on Horizon Pharma plc's Unsolicited Exchange Offer PR Newswire
08:19AM  Horizon Pharma Begins Hostile Bid for Depomed After Rebuffs at Bloomberg
08:04AM  Horizon pushes hostile Depomed bid with shareholder offer
Sep-04-15 06:15PM  Mystery, intrigue as biotech M&A explodes at
Sep-02-15 08:00AM  Depomed's Expanded Portfolio Of Pain Management Products Led By The NUCYNTA® Franchise To Be Highlighted At PAINWeek® 2015 PR Newswire
Sep-01-15 01:46PM  Smart Money Vs. Retail Investors: Level the Playing Field
Aug-31-15 07:21AM  Depomed Sets Record Date in Response to Horizon Bid at The Wall Street Journal -5.11%
06:16AM  DEPOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Aug-28-15 05:45PM  Wannabe buyer appeals to shareholders in contentious East Bay takeover at
03:28PM  This Analyst Loves Depomed And Its Nucynta Prescription
Aug-26-15 01:16PM  Depomed, Inc. Earnings Q2, 2015
Aug-21-15 01:59PM  'Haphazard approach' turns $2 billion East Bay takeover bid into snippy affair at
07:03AM  DEPOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Aug-20-15 10:00AM  Horizon Pharma's failed Depomed buyout -5.60%
Aug-19-15 06:32PM  Depomed rejects Horizon Pharma's offer for the third time
05:35PM  Depomed's Board of Directors Unanimously Rejects Revised Proposal from Horizon Pharma plc PR Newswire
Aug-17-15 07:05PM  Horizon Pharma Appears to Be on an Acquisition Spree
Aug-13-15 08:17PM  Horizon Pharma PLC -- Moody's: Horizon's new Depomed offer reduces upward credit pressure at Moody's
03:14PM  Horizon Pharma Talks to Depomed Holders About Adding Cash at Bloomberg
02:00PM  Depomed Comments on Horizon Pharma plc Letter PR Newswire
Aug-10-15 03:58PM  Investor Alert: Investigation of Depomed Announced by Holzer & Holzer, LLC Business Wire
06:08AM  DEPOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Aug-08-15 01:04PM  DEPOMED INC Financials
Aug-07-15 07:59PM  SHAREHOLDER ALERT: The Wagner Firm Announces Investigation of the Board of Directors of DepoMed, Inc. Business Wire +9.26%
05:25PM  Depomed goes hostile against Horizon Pharmas takeover bid at Fortune
01:50PM  Will Horizon Boost its Bid for DepoMed? at
12:46PM  Depomed Says Horizon Offered To Raise Bid Sort Of at Investor's Business Daily
11:10AM  DepoMed Fires Back at Horizon Pharma
07:31AM  Depomed Says Horizon Offered to Increase Its Takeover Bid at Bloomberg
06:30AM  Depomed Sends Letter to Horizon Pharma PR Newswire
Aug-06-15 02:07PM  What's Behind Depomed's Soaring Share Price in July? at Motley Fool
Aug-05-15 08:09PM  10-Q for Depomed, Inc. at Company Spotlight
11:02AM  Depomed to File Injunction Against Pursuer Horizon at The Wall Street Journal
Aug-04-15 10:50AM  Horizon and Depomed Sue Each Other Over Takeover Tactics at TheStreet
10:46AM  Shire Offers $30 Billion For Ex-Baxter Unit Baxalta at Investor's Business Daily
Aug-03-15 07:26PM  Horizon Sues to Knock Out Depomeds Poison Pill Takeover Defense at Bloomberg
10:53AM  DEPOMED INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
10:36AM  Horizon asks for Depomed vote, files lawsuit in hostile bid
10:17AM  Is a Vote on Depomed Takeover on the Horizon? at
10:10AM  Depomed Comments on Horizon Pharma Announcement PR Newswire
08:39AM  Horizon Pharma Pressures Depomed to Let Investors Vote on Offer at Bloomberg
07:47AM  Early movers: GS, PRE, SHLD, HZNP, TSN, T & more at CNBC
07:20AM  Depomed Holder Horizon Pharma Files Solicitation Statement
Jul-30-15 04:43PM  DEPOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
10:30AM  DEPO: DepoMed Reports Better Than Expected Product Sales
08:07AM  Depomed Rejected Horizon Pharma's Takeout Bid, But Still Trades As If M&A Is Happening
06:43AM  Ahead of the Bell: Depomed rejects Horizon offer
06:29AM  DepoMed downgraded by RBC Capital Mkts
Jul-29-15 10:08PM  Edited Transcript of DEPO earnings conference call or presentation 29-Jul-15 8:30pm GMT
05:52PM  Depomed reports 2Q loss
05:41PM  DepoMed Raises Guidance at The Wall Street Journal
04:30PM  Depomed Inc Earnings Call scheduled for 4:30 pm ET today
04:26PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Amendments to Articles of Inc. or Byla
04:08PM  Depomed Rejects Horizon Pharmas Takeover Proposal as Inadequate at Bloomberg
04:04PM  Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance PR Newswire
04:03PM  Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc PR Newswire
08:00AM  Depomed to Report Second Quarter Fiscal Year 2015 Financial Results on Wednesday, July 29, 2015 PR Newswire
Jul-28-15 08:01AM  The real reasons for the pharma merger boom at Fortune
02:14AM  Mandel's Lone Pine Takes Stake in Growing Horizon Pharma
Jul-24-15 04:40PM  Dealpolitik: Depomed Makes the Best of Weak Takeover Defenses at The Wall Street Journal
Jul-21-15 06:32PM  Horizon Raises Bid for Specialty Pharma Company Depomed at TheStreet
03:48PM  Horizon raises offer for rival drugmaker Depomed at Financial Times
12:44PM  Horizon Boosts Depomed Bid to About $2 Billion at The Wall Street Journal
12:33PM  Horizon Pharma raises bid for Depomed to $33 per share
12:00PM  Horizon Pharma raises offer again to buy reluctant Depomed
11:30AM  Horizon Pharma Raises Hostile Depomed Bid to $1.98 Billion at Bloomberg
11:23AM  Depomed Confirms Receipt of Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc PR Newswire
10:50AM  Horizon Pharma Raises Bid For Depomed; Both Stocks Up at Investor's Business Daily
08:04AM  Early movers: TRV, UTX, VZ, RF, DEPO, NKE & more at CNBC
07:12AM  Horizon Pharma raises offer for Depomed
Jul-20-15 06:50PM  Ethical-Drug Firms Horizon Pharma, Bristol-Myers Rally at Investor's Business Daily
11:57AM  Horizon Pharma Hits High As Q2 Sales Beat Street at Investor's Business Daily
11:20AM  Horizon Pharma Sees Record Quarter Ahead
09:47AM  Horizon Pharma CEO: Depotmed deal makes sense
Jul-16-15 09:33AM  Explainer: The Biotech raging bull at Financial Times
Jul-15-15 01:52PM  DepoMed Seen Holding Out for Higher Bid at
11:33AM  US biotech bull run sets scorching pace at Financial Times
Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company is involved in the clinical development of IW-3718 refractory gastroesophageal reflux disease program using Acuform drug delivery technology. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. The company also has a portfolio of royalty and milestone producing license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schoeneck James APresident and CEOSep 29Option Exercise6.4263,561408,15863,561Sep 29 07:24 PM
Vargas Thadd MSenior VP, BDJun 12Sale20.705,000103,500138,153Jun 15 05:16 PM
STAPLE PETER DDirectorMay 12Option Exercise6.1810,00061,80060,000May 12 09:23 PM
Schoeneck James APresident and CEOMay 12Option Exercise6.6645,679304,13461,411May 12 09:21 PM
Vargas Thadd MSenior VP, BDApr 08Option Exercise6.1854,710338,010143,153Apr 09 04:50 PM
Vargas Thadd MSenior VP, BDJan 20Option Exercise5.0319,00095,57088,443Jan 22 06:28 PM
Schoeneck James APresident and CEODec 19Option Exercise8.3640,700340,25256,432Dec 22 09:14 AM
Gosling Matthew MSenior VP, General CounselDec 02Sale15.858,819139,80832,501Dec 03 05:36 PM
Schoeneck James APresident and CEODec 02Sale15.8536,727582,23352,930Dec 03 05:35 PM
Vargas Thadd MSenior VP, BDDec 02Sale15.858,247130,74069,443Dec 03 05:35 PM
Moretti August JChief Financial OfficerDec 02Sale15.855,33984,63922,564Dec 03 05:35 PM
STAPLE PETER DDirectorNov 25Option Exercise5.0410,00050,40050,000Nov 26 04:38 PM
Gosling Matthew MSenior VP, General CounselNov 19Option Exercise6.1771,000438,07088,211Nov 21 08:00 PM
Gosling Matthew MSenior VP, General CounselNov 19Sale15.3671,0001,090,34717,211Nov 21 08:00 PM